Clinical observation of maintenance therapy with autologous cytokine-induced killer cells in patients with medium and advanced non-small cell lung cancer after first-line treatment

Shuxi SONG,Zhenyu DING,Yongye LIU,Huiying YU,Yinghui SUN,Yaling HAN,Dongchu MA,Xiaodong XIE
2015-01-01
Chinese Clinical Oncology
Abstract:Objective To investigate the efficacy and safety of maintenance therapy with autologous cytokine?induced killer cells(CIK) in patients with medium and advanced non?small cell lung cancer(NSCLC) after first?line treatment. Methods A total of 112 medium and advanced NSCLC patients with therapeutic effect of SD or above after first?line treatment were selected and assigned to treatment group(n= 56) and control group(n= 56) at random. The treatment group accepted maintenance therapy with autologous CIK cells after the first?line treatment. T lymphocyte subpopulations in peripheral blood were measured and the side effects were estimated according to NCI?CTC 4?? 0 version. Then, patients of both groups were followed up. Results The statuses of T lymphocyte subpopula?tion were improved after the therapy with autologous CIK cells and no side effects of grade 3?4 occurred. The median progression?free survival(PFS) of treatment group was 8?? 6 months, higher than 7?? 5 months of control group(P<0?? 05). The median overall survival (OS) in treatment group and control group were 19?? 2 and 18?? 6 months without significant difference(P>0?? 05). In treatment group, the median PFS in patients with therapeutic effect ≥50% PR?CR was 11?? 5 months, higher than 7?? 9 months in patients with <50%PR?SD and the difference was significant(P<0?? 05), but no difference was observed on the median OS between both subgroups(P>0?? 05). In control group, there was no significant difference on the median PFS and OS between patients with therapeutic effect ≥50%PR?CR or <50% PR?SD(P>0?? 05). In the cases whose therapeutic effect ≥50% PR?CR, the median PFS was 11?? 5 months in treat?ment group, higher than 8?? 8 months in control group with significant difference(P<0?? 05), but no difference was observed on the me? dian OS between both groups(P>0?? 05). Conclusion Maintenance therapy with autologous CIK cells in patients with medium and ad?vanced NSCLC after first?line treatment improves the immune function and enhances the ability of anti?tumor effect by natural immunity with a prolonged PFS and well?tolerated toxicity.
What problem does this paper attempt to address?